search
Back to results

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Buprenorphine transdermal delivery system
Sponsored by
Purdue Pharma LP
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Osteoarthritis, chronic pain, opioid, transdermal

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: documented history and/or radiologic evidence of chronic osteoarthritis of the hip or knee. receiving opioid therapy for osteoarthritis-related pain within the past year or have experienced pain that was inadequately controlled with a full standard dose of NSAIDs. Exclusion Criteria: receiving opioids at an average daily dose of greater than 90 mg of oral morphine equivalents or patients receiving more than 12 tablets or capsules per day of short-acting opioid-containing products scheduled to have surgery (including dental) during the study period that involved the use of pre- and/or postoperative analgesics or anesthetics. Other protocol-specific exclusion/inclusion criteria may apply.

Sites / Locations

  • Hawthorne & York, International, Ltd.
  • Arizona Research Center, LLC
  • ACRC/Arizona Clinical Research
  • Advanced Clinical Therapeutics
  • San Diego Arthritis and Osteoporosis Research
  • Scripps Clinic Rancho Bernardo
  • Clinical Research Consultants, Inc.
  • Tampa Bay Medical Research, Inc.
  • University Clinical Research
  • Gainesville Clinical Research Center
  • Physicians Research Associates Jacksonville
  • University Clinical Research, Inc.
  • Gold Coast Research, Inc.
  • MediSphere Medical Research Center, LLC
  • Westside Family Medical Center
  • Center for Pharmaceutical Research
  • NJP Clinical Research
  • PW Clinical Research, LLC
  • New Century Research Center, Ltd.
  • Altoona Center for Clinical Research
  • Mid-South Clinical Research Institute
  • Advanced Clinical Research

Outcomes

Primary Outcome Measures

Percentage of patients who were treated successfully for pain management
a patient fails if he or she discontinues early due to ineffective treatment or has a Patient Satisfaction Scale score of poor or fair at the final visit

Secondary Outcome Measures

Average pain intensity and patient satisfaction scores
Incidence of early discontinuation due to lack of efficacy
Time to early discontinuation due to lack of efficacy
Dose level at end of titration
Investigator's assessment of therapeutic response
Diary pain scores

Full Information

First Posted
April 12, 2006
Last Updated
April 29, 2006
Sponsor
Purdue Pharma LP
search

1. Study Identification

Unique Protocol Identification Number
NCT00314652
Brief Title
Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.
Official Title
A Double-Blind Placebo-Controlled Study of Buprenorphine Transdermal System (BTDS) in Patients With Osteoarthritis of the Hip or Knee
Study Type
Interventional

2. Study Status

Record Verification Date
April 2006
Overall Recruitment Status
Completed
Study Start Date
June 1999 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 1999 (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Purdue Pharma LP

4. Oversight

5. Study Description

Brief Summary
The objective of this study is to assess the safety and efficacy of the buprenorphine transdermal system (5, 10, and 20 mg) in comparison to placebo transdermal system in subjects with osteoarthritis pain. The double-blind treatment intervention duration is 28 days.
Detailed Description
Buprenorphine is a synthetic opioid analgesic with over twenty-five years of international clinical experience indicating it to be safe and effective in a variety of therapeutic situations for the relief of moderate to severe pain. Transdermal systems may offer advantages over currently indicated oral products including ease and convenience of use, improved compliance, possible reduction in patient care, and prolonged and consistent delivery of drug.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Osteoarthritis, chronic pain, opioid, transdermal

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
260 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Buprenorphine transdermal delivery system
Primary Outcome Measure Information:
Title
Percentage of patients who were treated successfully for pain management
Title
a patient fails if he or she discontinues early due to ineffective treatment or has a Patient Satisfaction Scale score of poor or fair at the final visit
Secondary Outcome Measure Information:
Title
Average pain intensity and patient satisfaction scores
Title
Incidence of early discontinuation due to lack of efficacy
Title
Time to early discontinuation due to lack of efficacy
Title
Dose level at end of titration
Title
Investigator's assessment of therapeutic response
Title
Diary pain scores

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: documented history and/or radiologic evidence of chronic osteoarthritis of the hip or knee. receiving opioid therapy for osteoarthritis-related pain within the past year or have experienced pain that was inadequately controlled with a full standard dose of NSAIDs. Exclusion Criteria: receiving opioids at an average daily dose of greater than 90 mg of oral morphine equivalents or patients receiving more than 12 tablets or capsules per day of short-acting opioid-containing products scheduled to have surgery (including dental) during the study period that involved the use of pre- and/or postoperative analgesics or anesthetics. Other protocol-specific exclusion/inclusion criteria may apply.
Facility Information:
Facility Name
Hawthorne & York, International, Ltd.
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85008
Country
United States
Facility Name
Arizona Research Center, LLC
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85023
Country
United States
Facility Name
ACRC/Arizona Clinical Research
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85712
Country
United States
Facility Name
Advanced Clinical Therapeutics
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85712
Country
United States
Facility Name
San Diego Arthritis and Osteoporosis Research
City
San Diego
State/Province
California
ZIP/Postal Code
92120
Country
United States
Facility Name
Scripps Clinic Rancho Bernardo
City
San Diego
State/Province
California
ZIP/Postal Code
92128
Country
United States
Facility Name
Clinical Research Consultants, Inc.
City
Trumbull
State/Province
Connecticut
ZIP/Postal Code
06611
Country
United States
Facility Name
Tampa Bay Medical Research, Inc.
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33761
Country
United States
Facility Name
University Clinical Research
City
Deland
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Gainesville Clinical Research Center
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32605
Country
United States
Facility Name
Physicians Research Associates Jacksonville
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
University Clinical Research, Inc.
City
Pembroke Pines
State/Province
Florida
ZIP/Postal Code
33024
Country
United States
Facility Name
Gold Coast Research, Inc.
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States
Facility Name
MediSphere Medical Research Center, LLC
City
Evansville
State/Province
Indiana
ZIP/Postal Code
47714
Country
United States
Facility Name
Westside Family Medical Center
City
Kalamazoo
State/Province
Michigan
ZIP/Postal Code
49009
Country
United States
Facility Name
Center for Pharmaceutical Research
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64114
Country
United States
Facility Name
NJP Clinical Research
City
Passaic
State/Province
New Jersey
ZIP/Postal Code
07055
Country
United States
Facility Name
PW Clinical Research, LLC
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27103
Country
United States
Facility Name
New Century Research Center, Ltd.
City
Beaverbrook
State/Province
Ohio
ZIP/Postal Code
45431
Country
United States
Facility Name
Altoona Center for Clinical Research
City
Duncansville
State/Province
Pennsylvania
ZIP/Postal Code
16635
Country
United States
Facility Name
Mid-South Clinical Research Institute
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Facility Name
Advanced Clinical Research
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84102
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Efficacy of the Buprenorphine Transdermal Delivery System in Subjects With Osteoarthritis Pain.

We'll reach out to this number within 24 hrs